PMHS Polomar Health Services, Inc.

OTC Pharmaceutical Preparations NV CIK: 0001265521
AI RATING
STRONG_SELL
92% Confidence

Investment Thesis

Polomar Health Services is in severe financial distress with a liquidity crisis that threatens near-term viability. The company operates with a dangerously thin cash position of $38.9K while burning $586K annually in operating cash flow, leaving minimal runway. Massive operating losses of $1.6M dwarf minimal revenue of $16.2K, indicating fundamental operational challenges despite a healthy gross margin.

Strengths

  • + 70.1% gross margin indicates viable product economics if revenue scaled
  • + Positive stockholders equity of $7.8M provides some balance sheet cushion
  • + Revenue grew 40.6% YoY from an admittedly small base

Risks

  • ! Critical liquidity crisis: current ratio of 0.13x and quick ratio of 0.03x indicate inability to cover short-term obligations
  • ! Cash reserves of only $38.9K with annual operating cash burn of $586K suggests imminent insolvency without capital injection
  • ! Operating losses of $1.6M vastly exceed $16.2K revenue, signaling fundamental business model failure at current scale
  • ! Negative operating and free cash flow with ongoing capital expenditures suggests unsustainable cash depletion trajectory
  • ! No insider trading activity suggests lack of management confidence in company trajectory

Key Metrics to Watch

Financial Metrics

Revenue
16.2K
Net Income
-1.7M
EPS (Diluted)
$-0.06
Free Cash Flow
-676.9K
Total Assets
9.3M
Cash
38.9K

Profitability Ratios

Gross Margin 70.1%
Operating Margin -9,939.1%
Net Margin -10,586.1%
ROE -22.0%
ROA -18.5%
FCF Margin -4,185.2%

Balance Sheet & Liquidity

Current Ratio
0.13x
Quick Ratio
0.03x
Debt/Equity
0.00x
Debt/Assets
16.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-14T10:42:21.925604 | Data as of: 2025-09-30 | Powered by Claude AI